Cingulate Inc (CING)

$0.48

-0.17

(-25.86%)

Market is closed - opens 7 PM, 12 Jul 2024

Insights on Cingulate Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 80.7% return, outperforming this stock by 177.7%

Performance

  • $0.47
    $0.56
    $0.48
    downward going graph

    2.08%

    Downside

    Day's Volatility :15.66%

    Upside

    13.87%

    downward going graph
  • $0.28
    $16.99
    $0.48
    downward going graph

    40.83%

    Downside

    52 Weeks Volatility :98.33%

    Upside

    97.17%

    downward going graph

Returns

PeriodCingulate IncIndex (Russel 2000)
3 Months
-47.85%
0.0%
6 Months
-93.21%
0.0%
1 Year
-97.0%
0.0%
3 Years
-99.46%
-22.5%

Highlights

Market Capitalization
6.1M
Book Value
$0.64
Earnings Per Share (EPS)
-19.52
Wall Street Target Price
14.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-215.86%
Return On Equity TTM
-1364.73%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-9.0M
EBITDA
-21.2M
Diluted Eps TTM
-19.52
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.06
EPS Estimate Next Year
-2.33
EPS Estimate Current Quarter
-1.16
EPS Estimate Next Quarter
-0.47

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Cingulate Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 2816.67%

Current $0.48
Target $14.00

Technicals Summary

Sell

Neutral

Buy

Cingulate Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cingulate Inc
Cingulate Inc
-31.37%
-93.21%
-97.0%
-99.46%
-99.46%
Moderna, Inc.
Moderna, Inc.
-16.86%
15.92%
-2.46%
-48.68%
764.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.12%
15.76%
50.37%
88.19%
269.25%
Novo Nordisk A/s
Novo Nordisk A/s
-2.42%
30.45%
80.67%
222.84%
488.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.43%
13.55%
42.21%
148.12%
179.95%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cingulate Inc
Cingulate Inc
NA
NA
NA
-2.06
-13.65
-2.16
NA
0.64
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cingulate Inc
Cingulate Inc
Buy
$6.1M
-99.46%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
764.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
269.25%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
488.09%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
179.95%
31.94
39.46%

Institutional Holdings

  • COWEN AND COMPANY, LLC

    1.53%
  • HRT FINANCIAL LLC

    0.17%
  • Tower Research Capital LLC

    0.13%
  • Bank of America Corp

    0.04%
  • GoalVest Advisory LLC

    0.02%
  • Advisor Group Holdings, Inc.

    0.01%

Company Information

Organization
Cingulate Inc
Employees
13
CEO
Dr. Shane J. Schaffer Pharm.D., PharmD
Industry
Miscellaneous

FAQs